17/03/2026 Celltrion announced that the tocilizumab SC formulation was now commercially available to patients in the US Celltrion announced that the tocilizumab SC formulation was now commercially available to patients in the US ( Ref ) Celltrion announced that AVTOZMA® (tocilizumab; IL-6 receptor antagonist) subcutaneous (SC) formulation was now commercially available to patients in the United States AVTOZMA® was among the first wave of tocilizumab biosimilars with both intr